Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining MER511, a Phase I therapy targeting ...
Amid proliferation of digital platforms for documentation and process execution, biopharma companies are exploring new ...
Large-scale validation of regenerative medicine, especially based on cell therapies, may come from cell therapies developed ...
Earlier this week, it was confirmed that a $380 million partnership between Bristol Myers Squibb (BMS) and contract ...
Bristol Myers Squibb subsidiary RayzeBio has committed to building a radiopharmaceutical manufacturing facility in Whitestown ...
Argentine biotech firm Biosidus tripled its cell culture capacity with a $12.9 million expansion to boost biosimilar ...
Industry expert Charley Maxwell shares essential strategies for biotech companies navigating Europe's fragmented regulatory ...
An expert from CTMC told BioProcess International how recent projects in Houston speak to the city’s drive to become a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results